Zepbound® (tirzepatide) 12.5 mg/0.5 mL Vial

Product Description: Zepbound® (tirzepatide) 12.5 mg/0.5 mL Vial

Zepbound® (tirzepatide) is a once-weekly injectable prescription medication used as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. The 12.5 mg/0.5 mL dosage is a high-potency therapeutic maintenance dose, typically indicated for patients who have progressed through lower titration steps and require this level to further their weight loss objectives.

Product Specifications

• Dosage Strength: 12.5 mg per 0.5 mL.

• Presentation: Single-dose vial (Requires the use of sterile, single-use syringes and needles for administration).

• Indication: Chronic weight management in adults with an initial BMI of $\ge 30\text{ kg/m}^2$ (obesity) or $\ge 27\text{ kg/m}^2$ (overweight) with at least one weight-related comorbid condition.

• Administration: Subcutaneous injection once weekly in the abdomen, thigh, or upper arm.

• Mechanism of Action: A highly potent dual agonist of the GIP and GLP-1 receptors. It modulates key metabolic pathways to induce significant weight loss by delaying gastric emptying and enhancing physiological satiety signals.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

Tirzepatide has been shown to cause thyroid C-cell tumors in rodent models. It is unknown whether Zepbound causes these tumors, including medullary thyroid carcinoma (MTC), in humans. Zepbound is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Clinical Considerations

• Dose Escalation & Monitoring: The 12.5 mg dose represents a significant level of metabolic modulation. Clinical monitoring for gastrointestinal adverse reactions (e.g., severe nausea, vomiting, or diarrhea) is essential, as these side effects are often more pronounced at higher dosages and can lead to dehydration or electrolyte imbalances.

• Contraindications: History of MTC/MEN 2; known serious hypersensitivity to tirzepatide or any product components.

• Preparation: Users must be proficient in sterile syringe techniques to ensure the exact volume (0.5 mL) is drawn and administered accurately on a weekly schedule.

• Hypoglycemia: There is an elevated risk of hypoglycemia when Zepbound is used concurrently with insulin or insulin secretagogues; clinicians should evaluate the need for concurrent medication dose reduction.

Storage and Handling

• Refrigeration: Maintain storage at 36°F to 46°F (2°C to 8°C).

• Room Temperature: If necessary, the vial may be stored at room temperature (up to 86°F or 30°C) for a maximum of 21 days.

• Stability: Store in the original carton to protect from light. Do not freeze. The solution must be clear and colorless to slightly yellow; do not administer if the solution appears cloudy or contains any visible particulate matter.

Disclaimer: This information is provided for professional reference only and does not constitute medical advice, diagnosis, or treatment. Always refer to the official FDA-approved Prescribing Information, Medication Guide, and Instructions for Use for comprehensive clinical guidance.